It’s official: With Monday’s news that pharmaceutical giants Pfizer Inc. and Allergan plc will join together in a tax inversion valued at $160 billion, 2015 is the year of the deal. The transaction brings total M&A value to $3.82 trillion for the year to date—4.3 percent higher than the record set in 2007, according to Mergermarket data.
The marriage of New York-based Viagra maker Pfizer and Dublin-based Botox maker Allergan, meanwhile, will likely go down as the deal of the year for an eager army of M&A lawyers.
